[1] Lopez-Beltran A,Scarpelli M,Montironi R,et al.2004 WHO classification of the renal tumors of the adults[J].Eur Urol,2006,49(5):798-805.
[2] Chen CJ,Hsu HT,Lin MT,et al.Renal cell carcinoma with t(X;17)(p11.2;q25) in a 5-year-old Taiwanese boy:a case report and review of the literature[J].Pathol Oncol Res,2012,18(1): 111-116.
[3] Argani P,Lal P,Hutchinson B,et al.Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions:a sensitive and specific immunohistochemical assay[J].Am J Surg Pathol,2003,27(6):750-761.
[4] 井颖,顾涛,王建林,等.小儿Xp11.2易位/TFE3基因融合相关性肾癌1例[J].临床小儿外科杂志,2015,14(2):157.
[5] 张雪,周胜利,苗重昌.XP11.2易位/TFE3基因融合相关性肾癌的CT诊断及鉴别诊断[J].医学影像学杂志,2015,25(6):1088-1090.
[6] 杨迷玲,李川,杨金花.Xp11.2易位/NONO-TFE3基因融合相关性肾癌1例[J].中华病理学杂志,2018,47(5):386-387.
[7] Huang JH,Zhou FJ.Research advances in Xp11.2 translocation renal cell carcinoma[J].Ai Zheng, 2008,27(9):1006-1008.
[8] 李世超,黄庆波,巩会杰,等.Xp11.2易位/TFE3融合基因相关性肾癌的外科治疗(附8例报告)[J].微创泌尿外科杂志,2015,4(2):114-116. |
